CardioPulmonary Resuscitation With Argon (CPAr) Trial
Key facts
- Who runs it
- Mario Negri Institute for Pharmacological Research
- Where
- Italy11 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 30 May 2022
- Planned end
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Noble gas Argon
- Record updated
- 17 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- ICU admission after resuscitation from witnessed non-traumatic out-of-hospital cardiac arrest (OHCA) of presumably cardiac etiology with a presenting shockable rhythm
- age ≥ 18 years
- unconsciousness after return of spontaneous circulation (ROSC)
- duration of CPR ≤ 40 mins
- initiation of study intervention ≤ 4 hrs from ROSC
- stable SaO2 ≥ 94% with a FiO2 of 30%
Who cannot take part
- CA of traumatic origin or from a non-presumably cardiac cause
- known terminal illness
- Non-witnessed CA
- CA with a non-shockable presenting rhythm (pulseless electrical activity and asystole)
- female of childbearing potential defined as younger of 50 years
- pregnancy
- pre-CA cerebral performance category (CPC) ≥ 3
- initiation of the study intervention > 4 hrs from ROSC
- participation to another clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Preclinical studies suggest that argon (Ar) might diminish the neurological and myocardial damage after any hypoxic-ischemic insult. Indeed, Ar has been tested in different models of ischemic insult, at concentrations ranging from 20% up to 80%. Overall, Ar emerged as a protective agent on cells, tissues and organs, showing less cell death, reduced infarct size and faster functional recovery. More specifically, encouraging data has been reported in animal studies on cardiac arrest (CA) in which a better and faster neurological recovery was achieved when Ar was used in the post-resuscitation ventilation. More importantly, these benefits have been replicated in different studies, enrolling both small and large animals. Finally, ventilation with Ar in O2 has been demonstrated to be safe both in animals and humans. Based on this evidence, a clinical translation is advocated. Thus, the CardioPulmonary resuscitation with Argon - CPAr trial has been conceived. The trial initially started as phase I-II trial to specifically address the question about the safety of the post resuscitation Ar-treatment. The available data on the first 30 randomized patients, evaluated by the Data Safety Monitoring Board (DSMB), were considered absolutely reassuring with regard to the safety of the experimental treatment. In this perspective, the DSMB supported the continuation of the study as a phase II trial, maintaining the study protocol in all its aspects. Thus, the aim of the CPAr trial is now to evaluate efficacy in reducing post-CA neurological injury of Ar/O2 ventilation in patients resuscitated from CA.
The 2 groups in the trial
- InterventionTreatment being tested
Patients will be ventilated with a mixture of Ar 70%/O2 30% for 4 hours
Treatment: Noble gas Argon
- Control-standardNo study treatment, for comparison
Ventilation with a FiO2 of 30% in room air is continued for 4 hours.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Record updated
- 17 September 2025